TY - JOUR T1 - Differential Mechanisms Mediating Descending Pain Controls for Antinociception Induced by Supraspinally Administered Endomorphin-1 and Endomorphin-2 in the Mouse JF - Journal of Pharmacology and Experimental Therapeutics JO - J Pharmacol Exp Ther SP - 1106 LP - 1111 VL - 294 IS - 3 AU - Masahiro Ohsawa AU - Hirokazu Mizoguchi AU - Minoru Narita AU - Mei Chu AU - Hiroshi Nagase AU - Leon F. Tseng Y1 - 2000/09/01 UR - http://jpet.aspetjournals.org/content/294/3/1106.abstract N2 - We have previously demonstrated that both endomorphin-1 and endomorphin-2 produce their antinociception by the stimulation of μ-opioid receptors. However, the antinociception induced by endomorphin-2 contains an additional component, which is mediated by the release of dynorphin A (1-17) acting on κ-opioid receptors. These studies were done to determine whether the antinociception induced by endomorphin-1 and endomorphin-2 given supraspinally was mediated by the activation of different descending pain control pathways in the mouse. Specific receptor antagonists or antisera against endogenous opioid peptides were injected intrathecally to block the receptors or bind the released endogenous opioid peptides, and endomorphin-1 or endomorphin-2 was then administered i.c.v. to activate the descending pain control systems to produce antinociception. The tail-flick response was used as antinociceptive test. The blockade of the α2-adrenoceptors and 5-hydroxytryptamine receptors in the spinal cord by i.t. injection of yohimbine and methysergide, respectively, inhibited the antinociception induced by i.c.v.-administered endomorphin-1 and endomorphin-2. However, the antinociception induced by endomorphin-2 was inhibited by i.t. pretreatment with δ2-opioid receptor antagonist naltriben or κ-opioid receptor antagonist nor-binaltorphimine, but not by the μ-opioid receptor antagonistd-Phe-Cys-Tyr-d-Try-Orn-Thr-Pen-Thr-NH2or the δ1-opioid receptor antagonist 7-benzylidene naltrexamine. Intrathecal pretreatment with antiserum against Met-enkephalin attenuated the antinociception induced by i.c.v.-administered endomorphin-2, but not endomorphin-1. Furthermore, i.t. pretreatment with antiserum against dynorphin A (1-17) also inhibited the antinociception induced by i.c.v.-administered endomorphin-2, but not endomorphin-1. Intrathecal pretreatment with antiserum against Leu-enkephalin or β-endorphin did not inhibit i.c.v.-administered endomorphin-1- or endomorphin-2-induced antinociception. The results indicate that, like other opioid μ-receptor agonists, morphine, and [d-Ala2,N-Me-Phe4, Gly5-ol]-enkephalin, endomorphin-1 and endomorphin-2 given i.c.v. produce antinociception by activating spinipetal noradrenergic and serotonergic pathways for producing antinociception. However, the antinociception induced by endomorphin-2 given i.c.v. also contains other components, which are mediated by the release of Met-enkephalin and dynorphin A (1-17) acting on opioid δ2- and κ-receptors, respectively, in the spinal cord. The American Society for Pharmacology and Experimental Therapeutics ER -